The Patent Finder

Precision Biologics, Inc.

Also on record
Records under this name other than the patents Precision Biologics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 24 patents it holds.

Showing 1 to 10 of 10 · Back to Precision Biologics, Inc.

PatentTitleStatus Expires Confidence
US 7,763,720Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
Term ended
Term ended Aug 22, 2026 · From the USPTO record
Term endedTerm ended Aug 22, 2026From the USPTO record
US 11,401,341Recombinant Monoclonal Antibodies and Corresponding Antigens for Colon and Pancreatic Cancers
Lapsed on the fee record
Ended Aug 2, 2026 · Low confidence
Lapsed on the fee recordEnded Aug 2, 2026Low confidence
US 10,364,295Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
Term ended
Term ended Jul 9, 2026 · From the USPTO record
Term endedTerm ended Jul 9, 2026From the USPTO record
US 7,314,622Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
Term ended
Term ended Apr 14, 2026 · From the USPTO record
Term endedTerm ended Apr 14, 2026From the USPTO record
US 9,605,077Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
Term ended
Ended no later than Apr 14, 2026 · From the USPTO record
Term endedEnded no later than Apr 14, 2026From the USPTO record
US 11,078,245Colon and Pancreas Cancer Peptidomimetics
Lapsed on the fee record
Ended Aug 3, 2025 · Medium confidence
Lapsed on the fee recordEnded Aug 3, 2025Medium confidence
US 9,034,588Monoclonal Antibody Therapy for Pancreas Cancer
Term ended
Term ended Apr 14, 2025 · Medium confidence
Term endedTerm ended Apr 14, 2025Medium confidence
US 8,470,326Monoclonal Antibody Therapy for Pancreas Cancer
Term ended
Term ended Jul 26, 2022 · Medium confidence
Term endedTerm ended Jul 26, 2022Medium confidence
US 9,592,290Monoclonal Antibody Therapy for Pancreas Cancer
Term ended
Term ended Mar 15, 2022 · Medium confidence
Term endedTerm ended Mar 15, 2022Medium confidence
US 11,001,641Monoclonal Antibody Therapy for Pancreas Cancer
Term ended
Term ended Mar 15, 2022 · Medium confidence
Term endedTerm ended Mar 15, 2022Medium confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited